Long-term risk of breast cancer after diagnosis of benign breast disease by screening mammography

Román, Marta; Louro, Javier; Posso, Margarita; Vidal, Carmen; Bargalló Castelló, Xavier; Vázquez, Ivonne; Quintana, María Jesús; Alcantara Souza, Rodrigo; Saladié, Francina; Riego, Javier del; Peñalva, Lupe; Sala, Maria; Castells, Xavier; BELE and IRIS Study Groups

doi:http://dx.doi.org/10.3390/ijerph19052625

Long-term risk of breast cancer after diagnosis of benign breast disease by screening mammography

License

Citation

Román M, Louro J, Posso M, Vidal C, Bargalló X, Vázquez I, Quintana MJ, Alcántara R, Saladié F, Del Riego J, Peñalva L, Sala M, Castells X, on behalf of the BELE and IRIS Study Groups. Long-term risk of breast cancer after diagnosis of benign breast disease by screening mammography. Int J Environ Res Public Health. 2022 Feb 24;19(5):2625. DOI: 10.3390/ijerph19052625

Abstract

Assessing the long-term risk of breast cancer after diagnosis of benign breast disease by mammography is of utmost importance to design personalised screening strategies. We analysed individual-level data from 778,306 women aged 50-69 years with at least one mammographic screening participation in any of ten breast cancer screening centers in Spain from 1996 to 2015, and followed-up until 2017. We used Poisson regression to compare the rates of incident breast cancer among women with and without benign breast disease. During a median follow-up of 7.6 years, 11,708 (1.5%) women had an incident of breast cancer and 17,827 (2.3%) had a benign breast disease. The risk of breast cancer was 1.77 times higher among women with benign breast disease than among those without (95% CI: 1.61 to 1.95). The relative risk increased to 1.99 among women followed for less than four years, and remained elevated for two decades, with relative risk 1.96 (95% CI: 1.32 to 2.92) for those followed from 12 to 20 years. Benign breast disease is a long-term risk factor for breast cancer. Women with benign breast disease could benefit from closer surveillance and personalized screening strategies.